Document is current

Article History

Received: 21 December 2023

Accepted: 21 June 2024

First Online: 26 September 2024

Declarations

:

: Ethics approval was obtained from the Conjoint Health Research Ethics Board (Ethics ID: REB13-1280) at the University of Calgary. Participants provided written, informed consent to participate in this trial.

: Not applicable.

: Maria Santana, Oyindamola Jaja, and Qiuli Duan declare no conflicts of interest. Erika Penz has received contracts/grants from the Canadian Institutes of Health Research, the Saskatchewan Health Research Foundation, the Respiratory Research Centre at the University of Saskatchewan, and AstraZeneca. Dr. Penz has received consulting fees from AstraZeneca and GlaxoSmithKline. Dr. Penz has also received payment or honoraria from AstraZeneca, COVIS Pharm, GlaxoSmithKline, Sanofi, and the Canadian Thoracic Society. Dr. Penz has received meeting/travel reimbursements from the Canadian Institute for Health Research– Cancer Research Institute Advisory Board for board-related activities. Dr. Penz serves in unpaid leadership or fiduciary roles with the Canadian Institute for Health Research– Cancer Research Institute Advisory Board, Canadian Institute for Health Research– Cancer Research Institute Advisory Board, and the Youth4Change advocacy group. Kristin Fraser has received a grant from Philips Respironics for investigator-led research. Patrick Hanly has been paid consulting fees by Dream Sleep Respiratory Services. Dr. Hanly has participated in a drug safety monitoring board or advisory board for Powell Mansfield. Sachin Pendharkar has received a grant from Jazz Pharmaceuticals. Dr. Pendharkar has been paid an honoraria from Jazz Pharmaceuticals, Paladin Labs, and the International Centre for Professional Development in Health and Medicine. Dr. Pendharkar also owns stock options in Atman Health.